Bcl-2 Expression and other clinicopathologic parameters in uterine leiomyosarcoma

Wiener Klinische Wochenschrift

Volumn 116, Issue 4, 2004, Pages 135-139

  Bodner, Klaus ^a   Bodner Adler, Barbara ^a   Kimberger, Oliver ^a   Czerwenka, Klaus ^a   Mayerhofer, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bcl 2 expression; Clinicopathologic parameters; Uterine LMS

Indexed keywords

PARAFFIN; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; UTERUS LEIOMYOSARCOMA;

EID: 1542380087     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03040751     Document Type: Article

References (37)

1. Zaloudek CJ, Norris HJ (1994) Mesenchymal tumors of the uterus. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract. Springer, New York, pp 849-914
2. Bell SW, Kempson RL, Hendrickson MR (1994) Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18: 535-558
3. Schwartz Z, Dgani R, Lancet M, Kessler I (1985) Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol 20: 354-363
4. Evans HL, Chawla SP, Simpson C, Finn KP (1988) Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 62: 2239-2247
5. Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Trope CG (1995) The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 34: 797-802
6. Van Dinh T, Woodruff JO (1982) Leiomyosarcoma of the uterus. Am J Obstet Gynecol 144: 817-823
7. Silverberg SG (1971) Leiomyosarcoma of the uterus. A clinicopathologic study. Obstet Gynecol 38: 613-628
8. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 67: 1107-1115
9. Sentman CL, Shutter JR, Hockenberry D, Kanagawa O, Korsmeyer SJ (1991) Bcl-2 inhibits multiple forms of apoptosis but not in negative selection in thymocytes. Cell 67: 879-888
10. Bissonette RP, Echeverri F, Mahboubi A, et al (1992) Apoptotic cell death reduced by c-myc is inhibited by bcl-2. Nature 359: 552-554
11. Williams GT (1991) Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098
12. Reed JC, Talwar HS, Cuddy M, Buffy G, Williamson J, Rapp UR, et al (1991) Mitochondrial protein p26 bcl-2 reduces growth factor requirements of NIH3t3 fibroblast. Exp Cell Res 195: 277-283
13. Tsujimoto Y, Croce CM (1986) Structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218
14. Matuso H, Maruo T, Samoto T (1997) Increased expression of bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82: 293-299
15. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6
16. Zhai Y-L, Nikaido T, Toki T, Shiozwawa A, Orii A, Fujii S (1999) Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus. Br J Cancer 80: 1658-1664
17. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481
18. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K (2003) Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study. J Reprod Med 48: 95-100
19. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, et al (1993) bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694
20. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al (1994) The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504
21. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, et al (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell-lung cancer. Br J Cancer 71: 1003-1007
22. Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K (2003) Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr 115: 191-195
23. Alenzi FQ, Warrens AN (2003) Cellular and molecular themes in apoptosis. Wien Klin Wochenschr 115: 563-574
24. Hockenberry DM (1994) Bcl-2 in cancer, development and apoptosis. J Cell Sci 18: 51-55
25. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, et al (1999) Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74: 196-201
26. Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, et al (1996) Apoptosis and immunhistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77: 255-264
27. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C, et al (1996) Apoptosis-related factors p53, bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol 149: 1941-1952
28. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A (2002) Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. Int J Gynecol Cancer 12: 286-289
29. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL (1988) Treatment of uterine leiomyosarcoma. Obstet Gynecol 71: 845-850
30. Hannigan EV, Freedman RS, Rutledge FN (1983) Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol 15: 56-64
31. Hannigan EV, Freedman RS, Elder KW, Rutledge FN (1983) Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophoshamide. Gynecol Oncol 15: 224-229
32. Hannigan EV, Freedman RS, Elder KW, Rutledge FN (1983) Treatment of advanced uterine sarcoma with adriamycin. Gynecol Oncol 16: 101-104
33. Thipgen T, Blessing JA, Yordan E, Valea F, Vaccarello (1996) Phase II trial of etoposide in leiomyosarcoma of the uterus: a gynecologic oncology study. Gynecol Oncol 63: 120-122
34. Hannigan EV, Gomez LG (1979) Uterine leiomyosarcoma. A review of prognostic clinical and pathologic features. Am J Obstet Gynecol 134: 557-564
35. Kempson RL, Hendrickson MR (1988) Pure mesenchymal tumors of the uterine corpus. Semin Diagn Pathol 5: 172-198
36. Vongatama V, Karlen JR, Piver SM, Tsukada Y, Moore RH (1976) Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri. Am J Roentgenol 126: 139-147
37. Peters WA, Kumar NB, Fleming WP, Morley GW (1984) Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 63: 550-556